ESR1 and breast carcinoma: Ly117018, which is a SERM and an analogue of raloxifene has been demonstrated to inhibit ER-positive human breast cancer cell proliferation.21 Raloxifene reduced the incidence of hormone-dependent breast cancer in postmenopausal women.22